Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 17/20 | 0.40 |
| ▸ | CASP3 | P42574 | 5/20 | 0.38 |
| ▸ | CASP7 | P55210 | 2/20 | 0.37 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28752849 | 1.00 | CASP1 (0.40) | CASP1CASP3CASP7CASP8HIF1A | |
| SCHEMBL80201 | 1.00 | CASP1 (0.40) | CASP1CASP3CASP7CASP8HIF1A | |
| SCHEMBL13632267 | 0.94 | CASP1 (0.35) | CASP1CASP3CASP7CASP8HIF1A | |
| SCHEMBL80126 | 0.92 | CASP3 (0.42) | CASP1CASP3HIF1A | |
| SCHEMBL87595 | 0.92 | CASP3 (0.42) | CASP1CASP3HIF1A | |
| SCHEMBL12569600 | 0.91 | CASP3 (0.47) | CASP1CASP3CASP7CASP8 | |
| SCHEMBL12625999 | 0.89 | BRAF (0.37) | HIF1A | |
| SCHEMBL77973 | 0.89 | CASP1 (0.42) | CASP1CASP3CASP7CASP8HIF1A | |
| SCHEMBL87380 | 0.89 | CASP1 (0.42) | CASP1CASP3CASP7CASP8HIF1A | |
| SCHEMBL27607559 | 0.89 | CASP1 (0.42) | CASP1CASP3CASP7CASP8HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129381-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129381-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-06 | — | — | US | disclosed |
| US-7960398-B2 | Potent inhibitors of TNF activity | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090281128-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281128-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-12 | — | — | US | disclosed |
| US-7553852-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-06-30 | — | — | US | disclosed |
| US-7553852-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-06-30 | — | — | US | disclosed |
| WO-2004002961-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281128-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP5, CASP3 | CASP1 1/4885CASP3 3/4885CASP7 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.